The American Society of Nuclear Cardiology (ASNC) has issued a position statement recommending that, if available, cardiac PET with myocardial blood flow should be used to evaluate all patients with suspected coronary artery disease (CAD) who are candidates for myocardial perfusion imaging.
The statement, published recently in the Journal of Nuclear Cardiology, emphasizes that extensive scientific research, worldwide clinical experience, and the latest practice guidelines affirm cardiac PET’s high diagnostic accuracy, powerful risk stratification, and low radiation exposure, the ASNC said in a January 26 news release.
Used in combination with the ASNC’s PET Model Coverage Policy, the new clinical indications statement is meant to encourage adoption of cardiac PET around the world and help U.S. practitioners address delays or denials of testing caused by insurers’ prior authorization policies, the society added.
